Testing a new type of radiotherapy using an MR-Linac device

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the feasibility of using a 1.5 T MR-Linac, a hybrid device that combines magnetic resonance imaging and a linear accelerator for radiotherapy. The approach aims to improve treatment precision by utilizing superior soft tissue contrast and enabling daily plan adaptations. By assessing the feasibility of imaging and treatment with this novel technology, the study seeks to enhance target volume coverage while minimizing damage to surrounding healthy tissues.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* existing indication for radiation therapy
* minimum age 18 years, no upper age limit
* capacity for consent
* Informed consent

Exclusion Criteria:

* contraindication for MRI (claustrophobia, metallic implants not applicable for MRI
* pregnancy

Where it's running

• University Hospital Tübingen, Department of Radiation Oncology
  Tübingen, Baden-Wurttemberg, Germany Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

• Collecting blood and leftover tumor tissue to test molecular residual disease (MRD) detection

  This project will test whether blood and leftover tumor tissue from adults with certain solid tumors can be used with Natera's MRD blood tests to find tiny amounts of cancer (ctDNA) after treatment.

  Recruiting Natera, Inc. · Austin, Texas · NCT07318051

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.